[Influence of Xianglingwan on dysmenorrhea and serum CA125 in treating patients with endometriosis].

article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-08

Xianglingwan treatment reduced dysmenorrhea symptoms and serum CA125 levels in patients with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To observe the influence of Xianglingwan on dysmenorrhea and serum CA125 in treating patients with endometriosis. METHOD: A total of 54 patients with endometriosis and without medical complications were random selected. Xianglingwan was administered from the fifth day of the menstrual cycle for 3 weeks every month as a therapeutic course, and three months for a therapeutic period. Pelvic type B ultrasonograph and blood CA125 were detected before and after treatment. Visual analogue scale was admitted to evaluate the dysmenorrhea. RESULT: The serum CA125 reduced obviously after therapy. There was a significant difference between them (P < 0.01). The symptom of dysmenorrhea also reduced obviously after treatment. There was a significant difference between them (P < 0.05). CONCLUSION: Xianglingwan can treat edometriosis effectively, and has less adverse reactions, it can also reduce the symptom of dysmenorrheal and the serum CA125.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosis

MeSH descriptors

CA-125 Antigen Drugs, Chinese Herbal Dysmenorrhea Dysmenorrhea Endometriosis Endometriosis Adult CA-125 Antigen Drugs, Chinese Herbal Dysmenorrhea Endometriosis Female Humans

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:14:30.652814+00:00
License: CC0 · commercial use OK